Titre
Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1.
Type
étude de cas
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Ayyoub, M.
Auteure/Auteur
Zippelius, A.
Auteure/Auteur
Pittet, M.J.
Auteure/Auteur
Rimoldi, D.
Auteure/Auteur
Valmori, D.
Auteure/Auteur
Cerottini, J.C.
Auteure/Auteur
Romero, P.
Auteure/Auteur
Lejeune, F.
Auteure/Auteur
Liénard, D.
Auteure/Auteur
Speiser, D.E.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
1078-0432
Statut éditorial
Publié
Date de publication
2003
Volume
9
Numéro
2
Première page
669
Dernière page/numéro d’article
677
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Comparative Study ; Journal Article ; Research Support, Non-U.S. Gov't - Publication Status: ppublish
Résumé
PURPOSE: As compared with natural tumor peptide sequences, carefully selected analog peptides may be more immunogenic and thus better suited for vaccination. However, T cells in vivo activated by such altered analog peptides may not necessarily be tumor specific because sequence and structure of peptide analogs differ from corresponding natural peptides. EXPERIMENTAL DESIGN: Three melanoma patients were immunized with a Melan-A peptide analog that binds more strongly to HLA-A*0201 and is more immunogenic than the natural sequence. This peptide was injected together with a saponin-based adjuvant, followed by surgical removal of lymph node(s) draining the site of vaccination. RESULTS: Ex vivo analysis of vaccine site draining lymph nodes revealed antigen-specific CD8+ T cells, which had differentiated to memory cells. In vitro, these cells showed accelerated proliferation upon peptide stimulation. Nearly all (16 of 17) of Melan-A-specific CD8+ T-cell clones generated from these lymph nodes efficiently killed melanoma cells. CONCLUSIONS: Patient immunization with the analog peptide leads to in vivo activation of T cells that were specific for the natural tumor antigen, demonstrating the usefulness of the analog peptide for melanoma immunotherapy.
PID Serval
serval:BIB_76A8B8796443
PMID
Date de création
2008-01-28T10:14:07.792Z
Date de création dans IRIS
2025-05-20T22:30:21Z